Skip to content

Study · Not a test of the peptide alone · 2020

11 results

Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.

Cosman F, McMahon D, Dempster D, Nieves JW

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research23 Oct 2019Cited by 16 (Europe PMC)

PMID31419313 (opens in a new tab)DOI10.1002/jbmr.3850 (opens in a new tab)PepBankPUB-31419313
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased lumbar spine BMD slightly more than cyclic treatment at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased lumbar bone density slightly more than cyclic treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD between regimens
    Study

    n = 70

    Comparator
    Cyclic teriparatide and denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    At 36 months, the LS BMD increase with standard was slightly larger than with cyclic (p = 0.04), but at 18 months, in the cyclic group, there was no decline in RAD or TBBM (p = 0.007 and < 0.001, respectively, versus standard).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, cyclic teriparatide and denosumab avoided radius BMD decline at 18 months compared with standard treatment.

    In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide and denosumab avoided forearm bone density decline compared with standard treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadius BMD at 18 months
    Study

    n = 70

    Comparator
    Standard sequential teriparatide and denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    At 36 months, the LS BMD increase with standard was slightly larger than with cyclic (p = 0.04), but at 18 months, in the cyclic group, there was no decline in RAD or TBBM (p = 0.007 and < 0.001, respectively, versus standard).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, cyclic teriparatide and denosumab avoided total body bone mineral decline at 18 months compared with standard treatment.

    In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide and denosumab avoided total body bone mineral decline compared with standard treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal body bone mineral at 18 months
    Study

    n = 70

    Comparator
    Standard sequential teriparatide and denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    At 36 months, the LS BMD increase with standard was slightly larger than with cyclic (p = 0.04), but at 18 months, in the cyclic group, there was no decline in RAD or TBBM (p = 0.007 and < 0.001, respectively, versus standard).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased lumbar spine BMD by 16% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased lumbar bone density by 16% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseStandard regimen lumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    LS BMD increment
    16%
    standard regimen at 36 months

    Source sentences

    Summary
    In the standard group, BMD increments at 36 months were: LS 16%, TH 4%, FN 3%, and TBBM 4.8% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased total hip BMD by 4% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased hip bone density by 4% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseStandard regimen total hip BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TH BMD increment
    4%
    standard regimen at 36 months

    Source sentences

    Summary
    In the standard group, BMD increments at 36 months were: LS 16%, TH 4%, FN 3%, and TBBM 4.8% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased femoral neck BMD by 3% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased femoral neck bone density by 3% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseStandard regimen femoral neck BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    FN BMD increment
    3%
    standard regimen at 36 months

    Source sentences

    Summary
    In the standard group, BMD increments at 36 months were: LS 16%, TH 4%, FN 3%, and TBBM 4.8% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased total body bone mineral by 4.8% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, standard sequential teriparatide and denosumab increased total body bone mineral by 4.8% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseStandard regimen total body bone mineral
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBBM increment
    4.8%
    standard regimen at 36 months

    Source sentences

    Summary
    In the standard group, BMD increments at 36 months were: LS 16%, TH 4%, FN 3%, and TBBM 4.8% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased lumbar spine BMD by 12% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased lumbar bone density by 12% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCyclic regimen lumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    LS BMD increment
    12%
    cyclic regimen at 36 months

    Source sentences

    Summary
    In the cyclic group, 36-month BMD increments were similar: LS 12%, TH 4%, FN 4%, and TBBM 4.1% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  9. 09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased total hip BMD by 4% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased hip bone density by 4% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCyclic regimen total hip BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TH BMD increment
    4%
    cyclic regimen at 36 months

    Source sentences

    Summary
    In the cyclic group, 36-month BMD increments were similar: LS 12%, TH 4%, FN 4%, and TBBM 4.1% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  10. 10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased femoral neck BMD by 4% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased femoral neck bone density by 4% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCyclic regimen femoral neck BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    FN BMD increment
    4%
    cyclic regimen at 36 months

    Source sentences

    Summary
    In the cyclic group, 36-month BMD increments were similar: LS 12%, TH 4%, FN 4%, and TBBM 4.1% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  11. 11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased total body bone mineral by 4.1% at 36 months.

    In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide and denosumab increased total body bone mineral by 4.1% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCyclic regimen total body bone mineral
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBBM increment
    4.1%
    cyclic regimen at 36 months

    Source sentences

    Summary
    In the cyclic group, 36-month BMD increments were similar: LS 12%, TH 4%, FN 4%, and TBBM 4.1% (all p < 0.001 versus baseline).
    1 context sentence
    Summary · context
    In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT07242612

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis

Khyber Medical University Peshawarn = 401 Oct 2025 to 15 Apr 2026

Osteoporosis · Osteoporosis, Postmenopausal

Trial pageClinicalTrials.govUpdated 13 Aug 2026
Status unknownPhase 4NCT02130973

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

Health Research, Inc.n = 60Aug 2013 to est. Aug 2018

Osteoporosis

Trial pageClinicalTrials.govUpdated 31 Aug 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.